In Reply We thank Drs Cui and Zhang for their comments on our Brief Report.1 We share their interest in studying tumor mutation burden (TMB)—a predictive biomarker associated with the probability that tumors of many different cancer histologies will respond to checkpoint inhibitor immunotherapy. It would be wonderful if the specific numerical value of TMB (in mutations per megabase) that optimally predicted immunotherapy response was the exact same number for every type of cancer and if that numerical value were a convenient number, like 10. Alas, the universe is not so simple.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Valero C, Chan TA, Morris LGT. Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker—Reply. JAMA Oncol. 2021;7(8):1245–1246. doi:10.1001/jamaoncol.2021.1870
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.